MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

29.21 +0.84 (+2.96%)
Official Closing Price Updated: 7:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October ↗
These stocks offer juicy yields and attractive risk-reward profiles. 
Via The Motley Fool
Topics Artificial Intelligence Economy Energy
News headline image
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%. 
Via MarketBeat
Topics Bonds Retirement
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers. 
Via The Motley Fool
Topics Intellectual Property
Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks ↗
Via Chartmill
News headline image
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
From Pfizer Inc
Via Business Wire
News headline image
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk. ↗
Pfizer has been going through a period of transition. 
Via The Motley Fool
Topics Earnings
News headline image
Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive ↗
Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell. 
Via The Motley Fool
Topics Economy
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,... 
Via MarketBeat
Topics ETFs
News headline image
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
From Pfizer Inc.
Via Business Wire
News headline image
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? ↗
While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗
Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
From Pfizer Inc.
Via Business Wire
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool
News headline image
5 Dividend Stocks Yielding Over 5% With Fortress Financial Profiles to Buy Now ↗
These high-yielding stocks offer very durable dividends. 
Via The Motley Fool
News headline image
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear. 
Via The Motley Fool
Topics Bonds Economy
News headline image
D-Wave Quantum vs. QuantumScape: Which Moonshot Tech Stock Is a Better Buy in 2026? ↗
Both companies are years from commercial scale and burning cash to get there. The difference is in how long each can keep going. 
Via The Motley Fool
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? ↗
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories. 
Via The Motley Fool
Topics Intellectual Property
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Treasury Yields Hit a 19-Year High—These 2 Bond ETFs Offer Monthly Income ↗
As bond yields climb amid record U.S. debt, Vanguard's BSV and VCIT ETFs offer TTM yields of about 4% and 5%, respectively, with potential for rising monthly distributions. 
Via MarketBeat
Topics Bonds ETFs
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved. 
Via MarketBeat
News headline image
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development... 
Via MarketBeat
Topics ETFs
News headline image
Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? ↗
These are among the highest-yielding stocks on the S&P 500. 
Via The Motley Fool
Topics Stocks
News headline image
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk. 
Via The Motley Fool
Topics Economy
News headline image
Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline ↗
Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief... 
Via MarketBeat
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗
These companies are committed to rewarding shareholders. 
Via The Motley Fool
News headline image
2 Large-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
CoreWeave vs. D-Wave Quantum: Is the AI Giant or the Quantum Computer Upstart the Better Stock Investment? ↗
Both are high-growth bets on unproven cutting-edge technologies. 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story